New diabetes combo shot aims to beat standard care in major china trial
NCT ID NCT07307235
First seen Jan 03, 2026 · Last updated May 19, 2026 · Updated 23 times
Summary
This study tests a new injectable medicine called iGlarLixi (a mix of insulin and a GLP-1 drug) against standard diabetes treatments in 1,316 adults in China whose type 2 diabetes is not well controlled with oral pills. The goal is to see if iGlarLixi lowers blood sugar better and helps with weight without causing more low blood sugar episodes. Participants will be randomly assigned to receive either iGlarLixi or standard care (basal or premixed insulin) for 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.